95 related articles for article (PubMed ID: 29738662)
1. Characterization of a Sulfated Anti-HIV Antibody Using an Expanded Genetic Code.
Li X; Hitomi J; Liu CC
Biochemistry; 2018 May; 57(20):2903-2907. PubMed ID: 29738662
[TBL] [Abstract][Full Text] [Related]
2. Homogeneous sulfopeptides and sulfoproteins: synthetic approaches and applications to characterize the effects of tyrosine sulfation on biochemical function.
Stone MJ; Payne RJ
Acc Chem Res; 2015 Aug; 48(8):2251-61. PubMed ID: 26196117
[TBL] [Abstract][Full Text] [Related]
3. A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection.
Dorfman T; Moore MJ; Guth AC; Choe H; Farzan M
J Biol Chem; 2006 Sep; 281(39):28529-35. PubMed ID: 16849323
[TBL] [Abstract][Full Text] [Related]
4. Mutagenesis and evolution of sulfated antibodies using an expanded genetic code.
Liu CC; Choe H; Farzan M; Smider VV; Schultz PG
Biochemistry; 2009 Sep; 48(37):8891-8. PubMed ID: 19715291
[TBL] [Abstract][Full Text] [Related]
5. Site-selective solid-phase synthesis of a CCR5 sulfopeptide library to interrogate HIV binding and entry.
Liu X; Malins LR; Roche M; Sterjovski J; Duncan R; Garcia ML; Barnes NC; Anderson DA; Stone MJ; Gorry PR; Payne RJ
ACS Chem Biol; 2014 Sep; 9(9):2074-81. PubMed ID: 24963694
[TBL] [Abstract][Full Text] [Related]
6. Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry.
Acharya P; Dogo-Isonagie C; LaLonde JM; Lam SN; Leslie GJ; Louder MK; Frye LL; Debnath AK; Greenwood JR; Luongo TS; Martin L; Watts KS; Hoxie JA; Mascola JR; Bewley CA; Kwong PD
ACS Chem Biol; 2011 Oct; 6(10):1069-77. PubMed ID: 21793507
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel anti-HIV-1 agents based on a broadly neutralizing antibody against the envelope gp120 V3 loop: a computational study.
Andrianov AM; Kashyn IA; Tuzikov AV
J Biomol Struct Dyn; 2014 Dec; 32(12):1993-2004. PubMed ID: 24251545
[TBL] [Abstract][Full Text] [Related]
8. A broad spectrum anti-HIV inhibitor significantly disturbs V1/V2 domain rearrangements of HIV-1 gp120 and inhibits virus entry.
Berinyuy E; Soliman ME
J Recept Signal Transduct Res; 2016; 36(2):119-29. PubMed ID: 26446906
[TBL] [Abstract][Full Text] [Related]
9. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
[TBL] [Abstract][Full Text] [Related]
10. Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies.
Qi Y; Jo S; Im W
Glycobiology; 2016 Mar; 26(3):251-60. PubMed ID: 26537503
[TBL] [Abstract][Full Text] [Related]
11. Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.
Xiang SH; Farzan M; Si Z; Madani N; Wang L; Rosenberg E; Robinson J; Sodroski J
J Virol; 2005 May; 79(10):6068-77. PubMed ID: 15857992
[TBL] [Abstract][Full Text] [Related]
12. [Virtual screening of small molecular HIV-1 entry inhibitor NC-2 targeting gp120 and its action mechanism].
Duan H; Wang Y; Song D; Chen Z; Qiu J; Lu L; Jiang S; Liu S; Tan S
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):826-31. PubMed ID: 23803191
[TBL] [Abstract][Full Text] [Related]
13. Sulfated Glycans in HIV Infection and Therapy.
Pomin VH; Bezerra FF; Soares PAG
Curr Pharm Des; 2017; 23(23):3405-3414. PubMed ID: 28137224
[TBL] [Abstract][Full Text] [Related]
14. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of small molecule-sulfotyrosine mimetics that inhibit HIV-1 entry.
Dogo-Isonagie C; Lee SL; Lohith K; Liu H; Mandadapu SR; Lusvarghi S; O'Connor RD; Bewley CA
Bioorg Med Chem; 2016 Apr; 24(8):1718-28. PubMed ID: 26968647
[TBL] [Abstract][Full Text] [Related]
16. Sulfotyrosine dipeptide: Synthesis and evaluation as HIV-entry inhibitor.
Ju T; Hu D; Xiang SH; Guo J
Bioorg Chem; 2016 Oct; 68():105-11. PubMed ID: 27475281
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a neutralizing monoclonal antibody to the external glycoprotein of HIV-1.
Pal R; di Marzo Veronese F; Nair BC; Rahman R; Hoke G; Mumbauer SW; Sarngadharan MG
Intervirology; 1992; 34(2):86-93. PubMed ID: 1284059
[TBL] [Abstract][Full Text] [Related]
18. Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy.
Flores A; Quesada E
Curr Med Chem; 2013 Feb; 20(6):751-71. PubMed ID: 23278399
[TBL] [Abstract][Full Text] [Related]
19. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
20. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
J Virol; 2017 May; 91(9):. PubMed ID: 28202762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
